Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lexaria BioscienceLEXX +11.60%41 Cash Ratio is 9.44 as of May. 2026, which is 43% below its 10-year median of 16.63. GuruFocus rates LEXX with a GF Score™ of 41/100 and a GF Value™ of $5.38 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,381 Biotechnology companies, Lexaria Bioscience ranks better than 78.13% on this metric.
Lexaria Bioscience has a Cash Ratio of 9.44. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Lexaria Bioscience's Cash Ratio or its related term are showing as below:
LEXX'
s Cash Ratio Range Over the Past 10 Years
Min: 0.21 Med: 16.63 Max: 76.81
Current: 9.44
During the past 13 years, Lexaria Bioscience's highest Cash Ratio was 76.81. The lowest was 0.21. And the median was 16.63.
LEXX's Cash Ratio is ranked better than 78.13% of 1381
companies
in the Biotechnology industry
Industry Median: 2.96
vs LEXX: 9.44
Lexaria Bioscience (NAS:LEXX) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Lexaria Bioscience Cash Ratio Related Terms
Lexaria Bioscience Cash Ratio Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a Cash Ratio of 9.44 as of May. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lexaria Bioscience and its competitors. This is 43% below median its historical median of 16.63. Over the past decade, Lexaria Bioscience's Cash Ratio has ranged from 0.21 to 76.81. According to the industry distribution chart, Lexaria Bioscience ranks #302 out of 1381 companies in the Biotechnology industry, placing it in the top 21.9%.
Is Lexaria Bioscience's Cash Ratio too high?
Lexaria Bioscience's current Cash Ratio of 9.44 is 43% below median its 10-year median of 16.63. Over the past 10 years, this metric has ranged from a low of 0.21 to a high of 76.81. The Biotechnology industry median Cash Ratio is 2.96. Lexaria Bioscience's value of 9.44 is 218.9% above this industry median. Based on the distribution chart, Lexaria Bioscience ranks #302 out of 1381 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Cash Ratio compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #302 out of 1381 companies for Cash Ratio. This places Lexaria Bioscience in the top 22% of its industry — outperforming the majority of peers. The industry median Cash Ratio is 2.96. Lexaria Bioscience's value of 9.44 is 218.9% above this benchmark. Historically, Lexaria Bioscience's own Cash Ratio has ranged from 0.21 to 76.81 over the past decade. While the company's 10-year median is 16.63 vs. the industry median of 2.96, Lexaria Bioscience has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.96, based on 1,381 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current Cash Ratio of 9.44 is 218.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.96 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current Cash Ratio is 9.44, which is 43% below median its own 10-year median of 16.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.38, compared to a current price of $8.84 — trading 64.3% above its estimated fair value. The current Cash Ratio is 9.44, which is 43% below median its 10-year median of 16.63 and 218.9% above the Biotechnology industry median of 2.96. Lexaria Bioscience's overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Cash Ratio is 9.44 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $8.84 is trading 64.3% above its estimated GF Value™ of $5.38.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
Cash Ratio: 9.44 (43% below median its 10-year median of 16.63)
GF Value™: $5.38 vs. price of $8.84 (64.3% above fair value)
Industry Position: 218.9% above the Biotechnology median (#302 of 1381)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
41GF Score
Get the complete analysis for LEXX
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
